Walgreens Globals

RYBELSUS® (semaglutide) tablets 3mg, 7 mg or 14 mg is a prescription medicine used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes.

• It is not known if RYBELSUS® can be used in people who have had pancreatitis
• RYBELSUS® is not for use in people with type 1 diabetes
• It is not known if RYBELSUS® is safe and effective for use in children under 18 years of age

• Key takeaways:

  • Rybelsus (semaglutide) is an oral medication approved to treat Type 2 diabetes. It contains the same active ingredient as Ozempic and Wegovy. Ozempic is approved for Type 2 diabetes, and Wegovy is approved for chronic weight management.

  • Rybelsus is currently being studied for weight loss in clinical trials. These studies involve higher doses than what’s currently approved and available for diabetes. 

  • Results show that an oral semaglutide (Rybelsus) dose of 50 mg results in similar weight loss as Wegovy. Due to these findings, Rybelsus’ manufacturer plans to request FDA approval in 2023. If approved for weight loss, it may be marketed under a different brand name.

Brand Names: Planep, Inspra (original brand name: Inspra)

Composition: Eplerenone

Strength: Available in 25mg and 50mg

Manufacturer: Various manufacturers

Packaging: Typically available in blister packs of 10 or 14 tablets

Treatment: Planep Tablet (Eplerenone) is primarily used for the treatment of high blood pressure (hypertension) and heart failure after a heart attack.

Product Description:
Planep Tablet contains Eplerenone, a selective aldosterone receptor antagonist. Aldosterone is a hormone that regulates sodium and water balance in the body, and by blocking its effects, Eplerenone helps to lower blood pressure and reduce the strain on the heart. This makes it beneficial for patients with hypertension and those recovering from a heart attack.

Common indications for Planep Tablet include:

• Hypertension: Used to lower blood pressure and reduce the risk of cardiovascular events such as strokes and heart attacks.
• Heart Failure Post-Myocardial Infarction: Helps to manage heart failure symptoms in patients who have had a heart attack, improving survival rates and reducing hospitalizations.

Dosage and Administration:
The typical starting dose of Planep Tablet for heart failure is 25 mg once daily, which may be increased to 50 mg once daily based on the patient's response. For hypertension, the dose may vary, often starting at 50 mg once daily. It is important to take Planep as prescribed by a healthcare provider, with or without food. Regular monitoring of blood pressure, kidney function, and potassium levels is necessary during treatment.

Common side effects of Planep Tablet may include:

• Hyperkalemia (high potassium levels)
• Dizziness or light-headedness
• Diarrhea
• Cough

Serious side effects, although rare, can include kidney dysfunction, severe hyperkalemia, or allergic reactions. Patients should be advised to avoid potassium supplements or potassium-rich foods unless directed by their healthcare provider.

Packaging:
Planep Tablets are typically available in blister packs containing 10 or 14 tablets, depending on the dosage and packaging by the manufacturer.

Planep Tablet (Eplerenone) is an effective medication for managing hypertension and heart failure, particularly in patients who have experienced a heart attack. Regular monitoring and adherence to the prescribed regimen are essential to achieving the best outcomes and minimizing potential side effects.

Brand Names: Empacon

Composition: Empagliflozin

Strength: 25mg

Manufacturer: Box of 90 Tablets

Packaging: Blister packs, typically containing 10 tablets

Treatment: Type 2 Diabetes Mellitus (T2DM)

Description:
Empacon 25mg contains Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor used in the treatment of Type 2 Diabetes Mellitus. It works by helping the kidneys remove glucose from the bloodstream through urine, thus lowering blood sugar levels.

Dosage:

• Adults: Typically 10-25 mg once daily, as prescribed by a healthcare provider.

Common Side Effects:

• Increased urination
• Urinary tract infections
• Thirst
• Hypoglycemia (especially when used with other diabetes medications)

Precautions:

• Not suitable for Type 1 diabetes or diabetic ketoacidosis.
• Monitor for signs of urinary infections and dehydration.
• Consult a doctor if you are pregnant, planning to become pregnant, or breastfeeding.

Note: Always use under medical supervision.

XARELTO® is a prescription medicine used to:

• reduce the risk of stroke and blood clots in adults who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body
• treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE)
• reduce the risk of blood clots from happening again in adults who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months
• help prevent a blood clot in the legs and lungs of adults who have just had hip or knee replacement surgery
• help prevent blood clots in certain adults hospitalized for an acute illness and after discharge, who are at risk of getting blood clots because of the loss of or decreased ability to move around (mobility) and other risks for getting blood clots, and who do not have a high risk of bleeding

XARELTO® is used with low dose aspirin to:

• reduce the risk of serious heart problems, heart attack and stroke in adults with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked)
• reduce the risk of a sudden decrease in blood flow to the legs, major amputation, serious heart problems or stroke in adults with peripheral artery disease (a condition where the blood flow to the legs is reduced) and includes adults who have recently had a procedure to improve blood flow to the legs

XARELTO® is used in children to:

• treat blood clots or reduce the risk of blood clots from happening again in children from birth to less than 18 years, after receiving at least 5 days of treatment with injectable or intravenous medicines used to treat blood clots
• help prevent blood clots in children 2 years and older with congenital heart disease after the Fontan procedure

XARELTO® was not studied and is not recommended in children less than 6 months of age who:

• were less than 37 weeks of growth (gestation) at birth
• had less than 10 days of oral feeding, or
• had a body weight of less than 5.7 pounds (2.6 kg)

XARELTO® is a prescription medicine used to:

• reduce the risk of stroke and blood clots in adults who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body
• treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE)
• reduce the risk of blood clots from happening again in adults who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months
• help prevent a blood clot in the legs and lungs of adults who have just had hip or knee replacement surgery
• help prevent blood clots in certain adults hospitalized for an acute illness and after discharge, who are at risk of getting blood clots because of the loss of or decreased ability to move around (mobility) and other risks for getting blood clots, and who do not have a high risk of bleeding

XARELTO® is used with low dose aspirin to:

• reduce the risk of serious heart problems, heart attack and stroke in adults with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked)
• reduce the risk of a sudden decrease in blood flow to the legs, major amputation, serious heart problems or stroke in adults with peripheral artery disease (a condition where the blood flow to the legs is reduced) and includes adults who have recently had a procedure to improve blood flow to the legs

XARELTO® is used in children to:

• treat blood clots or reduce the risk of blood clots from happening again in children from birth to less than 18 years, after receiving at least 5 days of treatment with injectable or intravenous medicines used to treat blood clots
• help prevent blood clots in children 2 years and older with congenital heart disease after the Fontan procedure

XARELTO® was not studied and is not recommended in children less than 6 months of age who:

• were less than 37 weeks of growth (gestation) at birth
• had less than 10 days of oral feeding, or
• had a body weight of less than 5.7 pounds (2.6 kg)

RYBELSUS® (semaglutide) tablets 3mg, 7 mg or 14 mg is a prescription medicine used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes.

• It is not known if RYBELSUS® can be used in people who have had pancreatitis
• RYBELSUS® is not for use in people with type 1 diabetes
• It is not known if RYBELSUS® is safe and effective for use in children under 18 years of age

• Key takeaways:

  • Rybelsus (semaglutide) is an oral medication approved to treat Type 2 diabetes. It contains the same active ingredient as Ozempic and Wegovy. Ozempic is approved for Type 2 diabetes, and Wegovy is approved for chronic weight management.

  • Rybelsus is currently being studied for weight loss in clinical trials. These studies involve higher doses than what’s currently approved and available for diabetes. 

  • Results show that an oral semaglutide (Rybelsus) dose of 50 mg results in similar weight loss as Wegovy. Due to these findings, Rybelsus’ manufacturer plans to request FDA approval in 2023. If approved for weight loss, it may be marketed under a different brand name.